Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
Clare Stirzaker, Ph.D.
Clare Stirzaker, Ph.D., is group leader and senior lecturer at the Garvan Institute of Medical Research, University of South Wales in Sydney, Australia.
More GEN Content From This Contributor
- Market and Technology Analysis: lncRNAs and Epigenetic Modulations: Potential Hotspots